The MIB1 LI was evaluated in 54 (91.5%) of the 59 study group patients: in all of the pituitary macroadenomas and in 34 of 39 microadenomas, i.e. in all the cases with a previously confirmed ACTH-staining pituitary adenoma. This evidence concerns the gene POMC and pituitary gland adenoma.